SCHEMBL1124329

SCHEMBL1124329

Cc1ccccc1/C=C/C(N)=O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.48
TSHR P16473 2/20 0.48
RAB9A P51151 3/20 0.47
LMNA P02545 3/20 0.46
HPGD P15428 1/20 0.46
HTT P42858 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
PTPN1 P18031 2/20 0.46
MAPT P10636 1/20 0.44
KDM4E B2RXH2 3/20 0.43
GMNN O75496 1/20 0.43
PMP22 Q01453 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
NFE2L2 Q16236 2/20 0.42
NFKB1 P19838 2/20 0.42
JUN P05412 1/20 0.42
CCNC P24863 1/20 0.42
CDK8 P49336 1/20 0.42
TFEB P19484 1/20 0.42
CA1 P00915 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30560932 1.00 ALDH1A1 (0.48) ALDH1A1TSHRRAB9ALMNAHPGD
SCHEMBL1124331 1.00 ALDH1A1 (0.48) ALDH1A1TSHRRAB9ALMNAHPGD
SCHEMBL28358892 1.00 ALDH1A1 (0.48) ALDH1A1TSHRRAB9ALMNAHPGD
SCHEMBL2328371 0.85 NFKB1 (0.50) LMNAHTTPTPN1MAPTKDM4E
SCHEMBL30560977 0.85 PTPN1 (0.40) ALDH1A1TSHRRAB9ALMNAHPGD
SCHEMBL5598954 0.83 NFE2L2 (0.61) ALDH1A1TSHRRAB9ALMNAMAPT
SCHEMBL5598952 0.83 NFE2L2 (0.61) ALDH1A1TSHRRAB9ALMNAMAPT
SCHEMBL17095076 0.83 CD44 (0.41) ALDH1A1TSHRRAB9ALMNAHPGD
SCHEMBL78556 0.82 CA1 (0.62) ALDH1A1TSHRRAB9ALMNAHTT
SCHEMBL2425317 0.82 CA1 (0.62) ALDH1A1TSHRRAB9ALMNAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2282996-A1 TETRAHYDROISOQUINOLINES AS ANTIMALARIAL AGENTS Actelion Pharmaceuticals Ltd. (CH) 2011-02-16 EP claimed
WO-2009141782-A1 TETRAHYDROISOQUINOLINES AS ANTIMALARIAL AGENTS ACTELION PHARMACEUTICALS LTD (CH) 2009-11-26 WO claimed
EP-1294707-A2 THIOPHENE DERIVATIVES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM Pharmacia Italia S.p.A. (IT) 2003-03-26 EP claimed
WO-2001098290-A2 THIOPHENE DERIVATIVES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM PHARMACIA ITALIA S.P.A. (IT) 2001-12-27 WO claimed
US-20250032448-A1 COMPOUND FOR USE IN THE TREATMENT AND/OR PREVENTION OF PARASITIC MEDIATED DISEASES KOH, Hwee Ling (SG) 2025-01-30 US disclosed
US-12144797-B2 Compound for use in the treatment and/or prevention of parasitic mediated diseases KOH, Hwee Ling (SG) 2024-11-19 US disclosed
US-20190046503-A1 COMPOUND FOR USE IN THE TREATMENT AND/OR PREVENTION OF PARASITIC MEDIATED DISEASES LEEWARD PACIFIC PTE LTD (SG) 2019-02-14 US disclosed
WO-2017114597-A1 PHARMACEUTICAL DOSAGE FORMS COMPRISING ((CIS)-N-(4-(DIMETHYLAMINO)-1,4- DIPHENYLCYCLOHEXYL)-N-METHYLCINNAMAMIDE Grünenthal GmbH (DE) 2017-07-06 WO disclosed
EP-2282996-A1 TETRAHYDROISOQUINOLINES AS ANTIMALARIAL AGENTS Actelion Pharmaceuticals Ltd. (CH) 2011-02-16 EP disclosed
WO-2010025235-A1 SELECTIVE LIGANDS FOR THE DOPAMINE 3 (D3) RECEPTOR AND METHODS OF USING THE SAME REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2010-03-04 WO disclosed
WO-2009141782-A1 TETRAHYDROISOQUINOLINES AS ANTIMALARIAL AGENTS ACTELION PHARMACEUTICALS LTD (CH) 2009-11-26 WO disclosed
US-6414013-B1 KINASE INHIBITORS; ANTICANCER AGENTS PHARMACIA & UPJOHN S.P.A. (IT) 2002-07-02 US disclosed
CN-1114834-A antidiabetic agent OTSUKA PHARMA CO LTD (JP) 1996-01-10 CN disclosed
EP-0670831-A1 QUINOXALINE DERIVATIVE AS ANTIDIABETIC AGENT OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1995-09-13 EP disclosed
WO-1995009159-A1 QUINOXALINE DERIVATIVE AS ANTIDIABETIC AGENT OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) 1995-04-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190046503-A1 COMPOUND FOR USE IN THE TREATMENT AND/OR PREVENTION OF PARASITIC MEDIATED DISEASES ICMT, ALG3, PFN1 ALDH1A1 583/4885TSHR 4854/4885RAB9A 1513/4885
US-12144797-B2 Compound for use in the treatment and/or prevention of parasitic mediated diseases ICMT, ALG3, PFN1 ALDH1A1 583/4885TSHR 4854/4885RAB9A 1513/4885
US-20250032448-A1 COMPOUND FOR USE IN THE TREATMENT AND/OR PREVENTION OF PARASITIC MEDIATED DISEASES EPX, PKD2, MPO ALDH1A1 764/4885TSHR 2855/4885RAB9A 651/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.